Logo image of ZNTL

ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Fundamental Analysis

NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD

1.66  -0.23 (-12.17%)

After market: 1.68 +0.02 (+1.2%)

Fundamental Rating

3

Overall ZNTL gets a fundamental rating of 3 out of 10. We evaluated ZNTL against 572 industry peers in the Biotechnology industry. ZNTL has a great financial health rating, but its profitability evaluates not so good. ZNTL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZNTL had negative earnings in the past year.
ZNTL had a negative operating cash flow in the past year.
In the past 5 years ZNTL always reported negative net income.
ZNTL had a negative operating cash flow in each of the past 5 years.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -39.78%, ZNTL perfoms like the industry average, outperforming 56.64% of the companies in the same industry.
ZNTL has a Return On Equity of -50.60%. This is in the better half of the industry: ZNTL outperforms 65.31% of its industry peers.
Industry RankSector Rank
ROA -39.78%
ROE -50.6%
ROIC N/A
ROA(3y)-43.93%
ROA(5y)-43.24%
ROE(3y)-55.01%
ROE(5y)-55.46%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZNTL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -50K -100K -150K -200K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ZNTL has been increased compared to 1 year ago.
ZNTL has more shares outstanding than it did 5 years ago.
ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

ZNTL has an Altman-Z score of -2.81. This is a bad value and indicates that ZNTL is not financially healthy and even has some risk of bankruptcy.
ZNTL has a Altman-Z score (-2.81) which is comparable to the rest of the industry.
ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.81
ROIC/WACCN/A
WACCN/A
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 7.29 indicates that ZNTL has no problem at all paying its short term obligations.
ZNTL has a Current ratio of 7.29. This is in the better half of the industry: ZNTL outperforms 68.67% of its industry peers.
A Quick Ratio of 7.29 indicates that ZNTL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.29, ZNTL is in the better half of the industry, outperforming 68.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 7.29
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.06% over the past year.
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ZNTL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.08% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.04%
EPS Next 2Y16.47%
EPS Next 3Y11.26%
EPS Next 5Y12.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZNTL. In the last year negative earnings were reported.
Also next year ZNTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.47%
EPS Next 3Y11.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZNTL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (1/30/2025, 8:00:02 PM)

After market: 1.68 +0.02 (+1.2%)

1.66

-0.23 (-12.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners108.18%
Inst Owner Change0.03%
Ins Owners3.12%
Ins Owner Change4.83%
Market Cap118.31M
Analysts77.65
Price Target9.69 (483.73%)
Short Float %7.04%
Short Ratio3.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-44.57%
Max EPS beat(2)39.67%
EPS beat(4)3
Avg EPS beat(4)28.36%
Min EPS beat(4)-44.57%
Max EPS beat(4)117.9%
EPS beat(8)5
Avg EPS beat(8)8.21%
EPS beat(12)7
Avg EPS beat(12)7.99%
EPS beat(16)8
Avg EPS beat(16)3.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.74%
EPS NY rev (1m)0%
EPS NY rev (3m)18.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.92
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-2.59
EYN/A
EPS(NY)-2.99
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.41
OCFYN/A
SpS0.57
BVpS4.97
TBVpS4.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.78%
ROE -50.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.93%
ROA(5y)-43.24%
ROE(3y)-55.01%
ROE(5y)-55.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.1%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 7.29
Altman-Z -2.81
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)450.59%
Cap/Depr(5y)428.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.11%
EPS Next Y46.04%
EPS Next 2Y16.47%
EPS Next 3Y11.26%
EPS Next 5Y12.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.58%
EBIT Next 3Y2.01%
EBIT Next 5YN/A
FCF growth 1Y-2.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.09%
OCF growth 3YN/A
OCF growth 5YN/A